The Indian Journal of Pediatrics

, Volume 85, Issue 11, pp 935–940 | Cite as

Newborn Screening for Congenital Hypothyroidism and Congenital Adrenal Hyperplasia

  • ICMR Task Force on Inherited Metabolic Disorders
Original Article



The Task Force formed by ICMR aimed at studying the prevalence of congenital hypothyroidism and congenital adrenal hyperplasia, the template disorders included in all newborn screening programs, and to evaluate the unidentified challenges in its execution in health care services. It also intended to evaluate the feasibility of newborn screening with regards to different geo-ethnic regions from India.


Five metropolitan centers identified had further 2 to 11 centers; both the urban and the rural sectors were included and were considered representative of the northern, southern, eastern, western and central parts of the country. A uniform protocol was developed to screen 100,000 neonates (20,000 from each center) beyond 34 wk of gestation for congenital hypothyroidism and congenital adrenal hyperplasia. Samples were collected by heel prick after 24 h of age. The parameters studied were prevalence of these diseases, percentage births covered, the turnaround time, recall rate and follow up of identified neonates as feasibility indicators. All centers participated in the Newborn Screening Quality Assurance Programme (NSQAP), of CDC, Atlanta, USA.


In the participating hospitals attached to the centers, 151,765 babies were intramural births. Of these 143,344 (94.5%) babies were eligible for screening. Amongst these births, a sample of 104,094 (73.2%) babies could be covered by the personnel. Overall prevalence of congenital hypothyroidism (CH) was 1 in 722 births; if babies with transient hypothyroidisms were excluded the prevalence was calculated to be 1:1130. The collective prevalence of congenital adrenal hyperplasia was 1 in 5762 with marked regional differences.


This collaborative study has demonstrated the feasibility of establishing a network of committed laboratories and scientists for executing newborn screening. This is expected to have a potential impact on morbidity and mortality and therefore this should be immediately taken up in a national newborn screening program.


Newborn screening Congenital hypothyroidism Congenital adrenal hyperplasia India 



Writing Group: Dr. Seema Kapoor, Dr. Madhulika Kabra, Dr. Mani Kalaiwani, Dr. Roli Mathur.

Steering Group: Late Dr. S. S. Aggarwal (Chairperson), Dr. I. C. Verma, Dr. Veena Kalra, Dr. Vasantha Muthuswamy and Dr. Vijay Kumar.


AIIMS, New Delhi: Dr. Vinod Paul, Dr. Ashok Deorari, Dr. Sheffali Gulati, Dr. Ramesh Agarwal, Dr. Vandana Jain, Dr. Suman Vashishst, Dr. Suneeta Mittal;

MAMC, Delhi: Dr. AP Dubey, Dr. Siddharth Ramji, Dr. Sangeeta Yadav, Dr. Swaraj Batra, Dr. Sangeeta Gupta;

KEM Hospital, Mumbai: Dr. Keya Lahiri, Dr. Ruchi Nanavati;

MEDISCAN, Chennai: Dr. Sujatha Jagadeesh, Dr. Sudha Rathna Prabhu, Dr. K Saraswathi, Dr. Rathna Kumari;

IPGMER, Kolkata: Dr. Mitali Chatterjee, Dr. S. C. Biswas, Dr. Indranil Chakraborty, Dr. Tapas Som, Meena Jaishankar, Dr. Satinath Mukhopadhyay;

Sandor, Hyderabad: Dr. A. I. Dherai and Dr. Srimannarayana Rao;

NIMHANS, Bangalore: Dr. D. Nagaraja.

Special Thanks to Mrs. Esha Chopra, Dr. Pallavi Vats, Mr. Amit Juneja, Dr. Neerja Gupta, Dr. Sudha Ratna Prabhu and all the staff in the project for its execution.

Indebted to: Late Dr. Taranath Shetty, NIMHANS, Bangalore and Late Dr. Suman Vashisht from AIIMS, New Delhi.


RRD, MK, SK, MM, AS, SS: Regional centres collected, analyzed the data and participated in patient care; RMP: Data coordination of the study; RM: Overall coordination of the study; PKN: Quality Assurance; RC: Laboratory tests; SK, MK, RM, KM, RMP: Wrote the manuscript; SK and MK will act as guarantors of the paper.

Compliance with Ethical Standards

Conflict of Interest


Source of Funding

Indian Council of Medical Research.


  1. 1.
    Desai MP, Colaco MP, Ajgaonkar AR, et al. Neonatal screening for congenital hypothyroidism in a developing country: problems and strategies. Indian J Pediatr. 1987;54:571–81.CrossRefGoogle Scholar
  2. 2.
    Desai MP, Upadhye P, Colaco MP, et al. Neonatal screening for congenital hypothyroidism using the filter paper thyroxine technique. Indian J Med Res. 1994;100:36–42.PubMedGoogle Scholar
  3. 3.
    Rama Devi AR, Naushad SM. Newborn screening in India. Indian J Pediatr. 2004;71:157–60.CrossRefGoogle Scholar
  4. 4.
    Wilson JMG, Jungner G. Principles and Practices of Screening for Disease. Geneva, Switzerland: World Health Organization; 1968. Report No.: Public Health Papers No. 34. Available at:
  5. 5.
    Devi AR, Rao AN, Bittles AH. Inbreeding and the incidence of childhood genetic disorders in Karnataka, South India. J Med Genet. 1987;24:362–5.CrossRefGoogle Scholar
  6. 6.
    Gupta SK, Pal DK, Tiwari R, et al. Impact of Janani Suraksha Yojana on institutional delivery rate and maternal morbidity and mortality: an observational study in India. J Health Popul Nutr. 2012;30:464–71.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Sankar MJ, Neogi SB, Sharma J, et al. State of newborn health in India. J Perinatol. 2016;36:S3–8.CrossRefGoogle Scholar
  8. 8.
    Yadav S, Gupta SK, Godbole MM, et al. Persistence of severe iodine-deficiency disorders despite universal salt iodization in an iodine deficient area in northern India. Public Health Nutr. 2010;13:424–9.CrossRefGoogle Scholar
  9. 9.
    Kaur G, Srivastav J, Jain S, et al. Preliminary report on neonatal screening for congenital hypothyroidism, congenital adrenal hyperplasia and glucose-6-phosphate dehydrogenase deficiency: a Chandigarh experience. Indian J Pediatr. 2010;77:969–73.CrossRefGoogle Scholar
  10. 10.
    Kaur G, Thakur K, Kataria S, et al. Current and future perspective of newborn screening: an Indian scenario. J Pediatr Endocrinol Metab. 2016;29:5–13.CrossRefGoogle Scholar
  11. 11.
    Sanghvi U, Diwakar KK. Universal newborn screening for congenital hypothyroidism. Indian Pediatr. 2008;45:331–2.PubMedGoogle Scholar
  12. 12.
    Agarwal M, Joshi K, Bhatia V, et al. Feasibility study of an outreach program of newborn screening in Uttar Pradesh. Indian J Pediatr. 2015;82:427–32.CrossRefGoogle Scholar
  13. 13.
    Gupta A, Srivastava S, Bhatnagar A. Cord blood thyroid stimulating hormone level – interpretation in light of perinatal factors. Indian Pediatr. 2014;51:32–6.CrossRefGoogle Scholar
  14. 14.
    Rashmi, Seth A, Sekhri T, Agarwal A. Effect of perinatal factors on cord blood thyroid stimulating hormone levels. J Pediatr Endocrinol Metab. 2007;20:59–64.Google Scholar
  15. 15.
    Chennuri VS, Mithbawkar SM, Mokal RA, Desai MP. Serum 17 alpha hydroxyprogesterone in normal full term and preterm vs sick preterm and full term newborns in a tertiary hospital. Indian J Pediatr. 2013;80:21–5.CrossRefGoogle Scholar
  16. 16.
    Kumar RA, Das H, Kini P. Newborn screening for congenital adrenal hyperplasia in India: what do we need to watch out for? J Obstet Gynaecol India. 2016;66:415–9.CrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2018

Authors and Affiliations

  • ICMR Task Force on Inherited Metabolic Disorders
    • 1
  1. 1.ICMR Task Force on Inherited Metabolic DisordersNew DelhiIndia

Personalised recommendations